Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OSBP | P22059 | 6/20 | 0.98 |
| ▸ | RORC | P51449 | 5/20 | 0.98 |
| ▸ | OSBP2 | Q969R2 | 3/20 | 0.98 |
| ▸ | USP2 | O75604 | 1/20 | 0.98 |
| ▸ | LMNA | P02545 | 1/20 | 0.98 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.98 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.98 |
| ▸ | NR1H3 | Q13133 | 7/20 | 0.85 |
| ▸ | GRIN1 | Q05586 | 6/20 | 0.83 |
| ▸ | GRIN2A | Q12879 | 6/20 | 0.83 |
| ▸ | CRYAB | P02511 | 1/20 | 0.79 |
| ▸ | HMGCR | P04035 | 1/20 | 0.79 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.79 |
| ▸ | ITGAV | P06756 | 1/20 | 0.79 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.79 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.79 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.78 |
| ▸ | DHCR24 | Q15392 | 1/20 | 0.76 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.74 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cholesterol SCHEMBL720337 | 1.00 | OSBP (0.98) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL21340667 | 0.99 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL22095727 | 0.99 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL20607477 | 0.99 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL23365796 | 0.99 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL21445079 | 0.99 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL23761109 | 0.99 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL23579652 | 0.99 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL21539517 | 0.99 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL21707472 | 0.99 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101796062-B | 6-disubstituted bicyclic nucleic acid analogs | ISIS PHARMACEUTICALS INC | 2014-07-30 | — | — | CN | claimed |
| CN-101107352-B | Apparatus and system having dry gene silencing compostions | DHARMACON INC | 2013-03-20 | — | — | CN | claimed |
| CN-101107352-A | Apparatus and system having dry gene silencing pools | DHARMACON INC (US) | 2008-01-16 | — | — | CN | claimed |
| CN-112424348-B | Novel RNA-programmable endonuclease system and uses thereof | 克里斯珀医疗股份公司 | 2024-12-31 | — | — | CN | disclosed |
| CN-118496292-A | Compounds and methods for reducing SNCA expression | IONIS制药公司 | 2024-08-16 | — | — | CN | disclosed |
| CN-118284434-A | Compositions and methods for skipping exon 45 in duchenne muscular dystrophy | 恩特拉达治疗学股份有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-118215504-A | Compounds and methods for skipping exon 44 in duchenne muscular dystrophy | 恩特拉达治疗学股份有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-112189053-B | Compounds and methods for reducing ATXN3 expression | IONIS制药公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-117915957-A | Compositions and methods for modulating mRNA splicing | 恩特拉达治疗学股份有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-117897176-A | Compositions and methods for modulating tissue distribution of intracellular therapeutic agents | 恩特拉达治疗学股份有限公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-111373043-B | Compounds and methods for reducing SNCA expression | IONIS制药公司 | 2024-01-02 | — | — | CN | disclosed |
| CN-101410406-A | 6-modified bicyclic nucleic acid analogs | ISIS PHARMACEUTICALS INC (US) | 2009-04-15 | — | — | CN | disclosed |
| CN-101341256-A | Recurrent gene fusions in prostate cancer | UNIV MICHIGAN (US) | 2009-01-07 | — | — | CN | disclosed |
| CN-101107352-A | Apparatus and system having dry gene silencing pools | DHARMACON INC (US) | 2008-01-16 | — | — | CN | disclosed |
| CN-101087804-A | Use of AIMP2DX2 for the diagnosis and treatment of cancer | SEOUL NAT UNIV IND FOUNDATION (KR) | 2007-12-12 | — | — | CN | disclosed |
| CN-1901939-A | Treatment of Proliferative Diseases Using Antisense IAP Oligomers and Chemotherapeutic Agents | AEGERA THERAPEUTICS INC (CA) | 2007-01-24 | — | — | CN | disclosed |
| CN-1882602-A | Modulation and degradation of hyaluronan synthesis in the treatment of disease | MEDITECH RES LTD (AU) | 2006-12-20 | — | — | CN | disclosed |
| CN-1860220-A | Dsrna induced specific and non-specific immunity in crustaceans and other invertebrates and biodelivery vehicles for use therein | MUSC FOUND FOR RES DEV (US) | 2006-11-08 | — | — | CN | disclosed |
| CN-1852974-A | Compositions and methods for treating and diagnosing cancer | UNIV MICHIGAN (US) | 2006-10-25 | — | — | CN | disclosed |
| CN-1780922-A | Compositions and methods for the treatment of severe acute respiratory syndrome (SARS) | ISIS PHARMACEUTICALS INC (US) | 2006-05-31 | — | — | CN | disclosed |